Predictors of Malignancy in Patients with Solitary and Multiple Thyroid Nodules

Heba Jaheen1 and Mahmoud Sakr2*

1Department of Surgery, Medical Research Institute, Egypt
2Department of Surgery, University of Alexandria, Egypt

Abstract

Introduction: Ultrasound (US) and Fine-needle aspiration (FNA) are the main methods used for investigating thyroid nodules, with questionable predictive values in multinodular goiter (MNG) compared to solitary thyroid nodule (STN).

Objective: To detect the independent predictors of malignancy in patients with solitary and multiple nodules.

Patients and methods: Medical records of patients who were admitted for thyroidectomy at Alexandria Main University Hospital and Medical Research Institute Hospital between January 2014 and January 2016 were reviewed. Demographic and clinical data, US reports, FNA reports (Bethesda “B” system), and final histopathological results were recorded and analyzed. Patients with hyper- or hypo-thyroidism, previous history of thyroid cancer or those with incomplete data were excluded.

Results: Collectively, 20% (111/554) of the study population proved to have malignancy on final histopathology, 19.3% (82/422) with MNG and 22% (29/132) with a STN. Combining gender and age showed that significantly more male patients with MNG under the age of 45 years had thyroid cancer ($X^2=11.75$, $p=0.003$): Statistically significant US features in the MNG Group included micro-calcifications, solid composition, echogenicity, incomplete halo, ill-defined margins, and suspicious cervical lymph nodes (LNs). In STN, significant US features included complex composition of nodules, peri-nodular vascularity, and also suspicious cervical LNs. The FNA results of BI-V reports showed that 16.9% (69/408) and 17.6% (22/125) of patients with MNG and STN, respectively, had false negative results. The risk of malignancy showed a significant rise from BI to BVI lesions in both Groups. Multivariate analysis revealed that, in MNG, the highest malignancy predictor was microcalcification, followed by FNA (BVI) and then suspicious cervical LNs. In STN, the features that retained significance in multivariate analysis were suspicious LNs & FNA.

Conclusion: Based on the data presented, it may be concluded that the independent predictors of malignancy were US findings of micro-calcification in patients with MNG, suspicious cervical LNs and Bethesda VI on FNA in patients with both MNG and STN.

Keywords: Predictors; Malignancy; Multinodular; Goiter; Solitary nodule; Ultrasound; FNA

Introduction

Thyroid nodules are a common clinical finding, with an estimated prevalence of 3% to 7% on the basis of palpation [1-3]. They are more common in the elderly, in women, and in presence of iodine deficiency and history of exposure to radiation [1]. Diagnosis of multinodular goiter (MNG) should rely on ultrasound (US) examination since approximately 20%-50% of patients diagnosed clinically as having a solitary thyroid nodule (STN), are found to have additional nodules on US [1,4,5]. The mean incidence of malignancy in thyroid nodules is 14% [6,7], which increased markedly in recent years due to the wide application of high resolution US and fine-needle aspiration (FNA) [8,9]. While patients with MNG have been reported to have the same risk of malignancy as those with STN [10-12], Other authors reported a higher likelihood of malignancy for STN [10,13]. The present study was conducted to detect the independent predictors of malignancy in patients with MNG as compared to STN.

Patients and Methods

Study population

The medical records of 1217 patients who were admitted to Alexandria Main University Hospital and Medical Research Institute Hospital, between January 2014 and January 2016, were retrospectively reviewed. After excluding patients with hyper- or hypo-thyroidism or history of thyroid cancer, and those with incomplete data, patients who underwent thyroidectomy for euthyroid MNG (Group 1, n=422) or STN (Group 2, n=132) were included in the present study, and constituted the study population (n=554).

Demographic and clinical data

Age, gender, family history of thyroid cancer, previous history of irradiation or thyroid surgery, clinical presentation on admission, and retrosternal extension were all recorded.

Imaging data

The solitary nodule and the largest or most suspicious nodule (in case of MNG) were evaluated in the reviewed reports regarding the

*Corresponding author: Mahmoud Sakr, MD, PhD, FACS, Professor of Surgery, Faulty of Medicine, Head, Neck, and Endocrine Surgery Unit, University of Alexandria, 311Horreya Road, Cleopatra, Alexandria, Egypt, Tel: +002 01007834993; E-mail: mah_sakr@yahoo.com

Received August 25, 2016; Accepted September 06, 2016; Published September 12, 2016

Citation: Jaheen H, Sakr M. Predictors of Malignancy in Patients with Solitary and Multiple Thyroid Nodules. Journal of Surgery [Jurnalul de chirurgie]. 2016; 12(3): 105-110 DOI:10.7438/1584-9341-12-3-3

Copyright: © 2016 Jaheen H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
following parameters; echogenicity, calcifications, halo, margins, composition (solid, cystic, mixed), size (divided according to maximum diameter/nodule into <2 cm, 2-4 cm, >4 cm), vascularity (Doppler examination), and the presence of suspicious cervical lymph nodes (LNs) (rounded, >0.5 cm, lost hilum, peripheral vascularization, cystic changes, and calcification).

**Histopathological data**

The Bethesda system for reporting thyroid cytopathology (BI-BVI) was adopted in this study, where BI is non-diagnostic or unsatisfactory, BI is benign, BI is means atypical or follicular lesion with undetermined significance, BIV is follicular neoplasm, BV is suspicious of malignancy and BVI is malignant. Predictive indices of FNA were calculated to detect the utility of (B-VI) in diagnosing malignancy. All of the available data for each patient were compared to final histopathology.

**Statistical analysis**

Data were analyzed using IBM SPSS software package version 20.0 (Belmont, Calif. 2013). Qualitative data were described using number and percent. Comparison between different groups regarding categorical variables was tested using Chi-square test. When more than 20% of the cells have expected count less than 5, correction for chi-square ($\chi^2$) was conducted using Fisher’s exact test or Monte Carlo correction. Quantitative variables were presented as mean and standard deviation of the mean and were compared using the Student t test. Univariate and multivariate logistic regression were used. A $p$-value of <0.05 was considered to be statistically significant.

**Results**

Collectively, 20% (111/554) of the study population proved to have malignant disease on final histopathology (Table 1), 82 patients (19.3%, 82/422) belonged to the MNG Group and 29 (22%, 29/132) belonged to the STN Group, with no significant differences between both ($X^2=0.504, p=0.252$). Table 2 shows the demographic and clinical data of patients with thyroid cancer in both Groups. Male patients with MNG had insignificantly more cancer than female patients (29.5% versus 18.3%, respectively). In the STN Group, female patients had insignificantly more cancer as compared to male patients (23% versus 13.3%, respectively). Family history of thyroid cancer was significantly more in patients with STN ($X^2=4.156, p=0.042$). Combining gender and age with a cut-off point at 45 years (Table 3) showed significant differences in MNG only, where more male patients under the age of 45 years (47.1%) had cancer as compared not only to female patients in the same age group (14.8%) ($X^2=11.75, p=0.003$), but also to male patients above the age of 45 years (18.5%) ($X^2=4.08, p=0.043$). On the other hand, thyroid cancer was encountered more in female patients above the age of 45 years (24.4%) as compared to those below 45 years (14.8%) ($X^2=5.39, p=0.020$). The majority of patients (95.1%) presented with a slowly progressive neck swelling with or without dyspnea and/or dysphagia not related to any other systemic disease. None of the patients presented with hoarseness of voice. There was no statistically significant difference in malignancy occurrence between patients with retrosternal extension (RSE) (9.7%) and those without (17.5%) ($\chi^2=1.237, p=0.266$) in the MNG Group. Only two patients with STN had RSE, and they proved to have benign thyroid pathology ($\chi^2=0.530, p=1.000$). Table 4 summarizes the US features in both Groups. As may be seen, statistically significant features predictive of cancer in the MNG Group included micro calcification, solid composition, echogenicity, incomplete halo, and ill-defined margins. In addition, 11 patients out of 21 (52.4%) with suspicious cervical LNs had malignant disease ($\chi^2=19.09, p<0.001$). Statistically significant US features in the STN Group included complex composition of nodules and peri-nodular vascularity. Moreover, all 5 patients with suspicious cervical LNs in this Group proved to have malignant thyroid disease ($\chi^2=20.229, p<0.001$). Although, largest nodules (> 4 cm) in patients with MNG or STN had the highest rate of malignancy (22.4% and 31.8%, respectively), yet, there was no statistically significant difference regarding nodule size and occurrence of malignancy. The collective reports of BI–BV FNA results (non-malignant) revealed that 17.4% (91/523) turned out to be malignant on final histopathology. Accordingly, 16.9% (69/408) and 17.6% (22/125) of patients with MNG and STN, respectively, had false negative results. On the other hand, BVI FNA (malignant), showed one false positive case (1/14, 8.3%) in patients with MNG as compared to none in those with STN (Table 5). The risk of malignancy showed a significant rise from BIV to BVI lesions in both Groups as shown in Figure 1. Multivariate analysis of predictors of malignancy in MNG revealed that the highest predictor was micro-calcification, followed by FNA (BVI) and then the presence of suspicious cervical LNs (Table 6). In STN, predictors that retained significance in multivariate analysis were the presence of suspicious cervical LNs and BVI FNA.

**Discussion**

The clinical importance of thyroid nodules rests with the need to exclude thyroid cancer [2,10,14-16]. In the current study, 19.4% of MNG patients and 22% of STN patients had malignant disease on final histopathology. Similar results were reported by other authors, with a malignancy rate of 5.7%-31% in MNG [2,13,15,17-31] and 17% in STN [32] with no significant difference between both [13,19,32-38]. Thus, the likelihood of thyroid cancer seems to be independent from the number of nodules [13-39]. The difference in the reported rates of malignancy among patients with MNG and STN in the above studies undoubtedly reflects differences in the selection criteria used for analysis, as well as geographic differences in the population studied [19]. Several authors reported that detection of malignancy did not correlate with patient’s gender, which is in accordance with the current findings [12,20,40,41]. Other studies however, reported higher rates of thyroid carcinoma in male patients [13,31] especially in patients with follicular neoplasm (BII, BIV) [13,15,17,27,31,42-47]. While some authors reported that older age is an independent risk factor of malignancy [29,31,45,46,48-51], others, in accordance with our findings, found no correlation with age in patients with solitary or multiple nodules [12,13,15,16,20,40,41]. In a study by Luo et al. [15], age lost its significance as an independent risk factor for thyroid malignancy when included in a multivariate analysis, suggesting that age is not a very strong independent risk factor for malignancy and will likely not be helpful in predicting the risk of malignancy in a given patient. On the other hand, some investigators found that older age is significantly correlated with the presence of benign neoplasms in thyroid nodules [42,52]. This wide contradiction is probably due to differences in patients selection and numbers of the study population [1,10,13,53]. It is conceivable that both gender and age are weak independent risk factors, but perhaps they add value when combined together as a single index of risk prediction, as shown in the present study that showed a higher risk in male patients with MNG less than 45 years. Combining high resolution US with FNA in evaluating thyroid nodules is considered the modality of choice in investigating nodular

![Table 1: Final histopathology of malignant tumors in patients with MNG and STN](https://journals.fdi.okstate.edu/journals/3j-surgery/images/2020-3-3j_surgery_table1.png)

**Table 1:** Final histopathology of malignant tumors in patients with MNG and STN

| US Features | MNG (N=422) | STN (N=132) |
|-------------|-------------|-------------|
| Papillary thyroid carcinoma (PTC) | 70 | 85 | 21 |
| Follicular thyroid carcinoma (FTC) | 8 | 4 | 0 |
| Medullary thyroid carcinoma (MTC) | 2 | 2 | 0 |
| Hurthle cell carcinoma (HCC) | 1 | 0 | 0 |
| Anaplastic thyroid carcinoma +PTC | 1 | 0 | 0 |
| Anaplastic thyroid carcinoma (ATC) | 0 | 0 | 0 |
| **Total** | **82** | **100** | **29** |

**Volume 12 • Issue 3 • 3J Surgery, an open access journal**

**ISSN: 1584-9341**
thyroid gland [1,26]. Out of the analyzed US features in this study, micro calcification, solid composition, incomplete halo, and ill-defined margins were significant risk factors in patients with MNG, in addition to suspicious cervical lymph nodes in both Groups. Similar results were reported by other studies that investigated the risk of malignancy in MNG alone [20,54-57], or in both MNG and STN [51,54,58-61]. Ultrasound features cannot accurately distinguish between benign and malignant thyroid disease. Although certain sonographic features are associated with increased risk of malignancy, the predictive value of these criteria are not sufficiently high or low to preclude the missing of FNA, and it is recommended that US features are used in combination with FNA and clinical presentation to reach the proper management [12,13,51,58,62,63].

Cytopathological examination is the cornerstone in appraising the malignant potential of a given thyroid nodule. A meta-analysis study reported non-diagnostic incidence rate (BI) between 1.8% and 23.6%, with a collectively reported malignancy rate of 16.8% [8]. In the current study, three of 9 patients (33.3%) who were classified as BI had cancer. This high rate could be attributed to several factors; not all FNA in the present study were obtained under US guidance, no on-site smear adequacy assessment was adopted, not all reviewed FNA reports were performed by the same pathologist, and most of biopsied nodules were large in size (≥ 4 cm), which may be associated with a high malignancy rate, reaching 27% as reported by Pinchot et al. [31] and Gharib et al. [1]. In this study, 8.4% of BII patients had false negative results (i.e. malignant disease). The false negative rate of 0-8% was reported by several authors [8,10,17,64,65], with the rate being higher in large nodules (≥ 4 cm) [10,31,66]. In this study, the rate of malignancy increased with increasing Bethesda rating from BIV to BVI. Similar findings were reported in the literature with an average rate of malignancy of 1.2%-25.3% in BIV [6,8,17,46,67,68] 60%-75%

### Table II: Demographic and clinical data of patients with malignant disease in both Groups (MNG and STN)

| Demographic and clinical data | MNG (N=2422) | STN (N=132) | χ² (p) |
|-----------------------------|--------------|------------|--------|
| Gender                      | Male         | 13/44 (29.5%) | 2/15 (13.3%) | 1.55 (0.213) |
|                            | Female       | 69/378 (18.3%) | 27/117 (23%) | 1.3 (0.249) |
| Age (years)                 | < 45         | 3.210 (0.073) | 0.736 (0.391) |
|                            | > 45         | 44/260 (16.9%) | 15/80 (18.8%) | 0.142 (0.706) |
| Previous surgery            | Male         | 12/58 (20.7%) | 1/2 (50%) | 0.979 (0.322) |
|                            | Female       | 0/1 (100%) | 0/1 (100%) |
| Family history of thyroid cancer | 0/11     | 2/6 (33.3%) | 4.156 (0.042*) |
| Radiation history           |             | 0/2 | 0/0 |

* P<0.05

### Table III: Incidence of malignancy in patients with MNG and STN in relation to gender and age combined together

| Gender | Age | MNG (N=82) | STN (N=29) | χ² (p) |
|--------|-----|------------|------------|--------|
| Male   | < 45 | 8/17 (47.1%) | 5/27 (18.5%) | 4.082 (0.043*) |
| Female | < 45 | 36/243 (14.8%) | 33/135 (24.4%) | 5.39 (0.020*) |
|       | > 45 | 18/162 (23.4%) | 10/52 (19.2%) | 1.391 (0.238) |

### Table IV: Ultrasound (US) features in patients with MNG and STN

| Feature               | N (MNG) | % (MNG) | N (STN) | % (STN) | χ² (p) |
|-----------------------|---------|---------|---------|---------|--------|
| Hypoechoic            | 78       | 21.6%   | 16      | 27.3%   | 0.757 (0.396) |
| Micro-calcification    | 527      | 18.5%   | 15      | 23.2%   | 1.520 (0.219) |
| Solid                 | 64.3     | 10.55%  | 10      | 16.4%   | 3.59 (0.020*) |
| Incomplete halo       | 139      | 18.7%   | 5       | 12.5%   | 0.01 (0.920) |
| Ill-defined margins    | 62.5     | 37.5%   | 6       | 37.5%   | 0.01 (0.920) |
| Peri-nodular vascularity | 77.3      | 22.7%   | 5       | 37.5%   | 0.01 (0.920) |
| Intra-nodular vascularity | 64.3      | 35.7%   | 6       | 37.5%   | 0.01 (0.920) |
| Cervical LNs           | 47.6     | 52.4%   | 10      | 100%    | 20.229 (<0.001) *|

### Table V: FNA (Bethesda System) [6] results as diagnostic test for malignancy

| Bethesda System | Benign (N=340) | Malignant (N=82) | Benign (N=103) | Malignant (N=29) | χ² (p) |
|-----------------|---------------|------------------|---------------|------------------|--------|
| B (II-V)        | 337           | 83.6%            | 66            | 16.4%            | 33.232 (<0.001)* |
| BVI             | 1             | 7.1%             | 13            | 92.9%            | 9.075 (p=0.003)* |

* P<0.05

* χ²: Chi square test

*: Statistically significant at p ≤ 0.05

**: Patients with BI-FNA were not included (MNG Group, n=5 – STN Group, n=3)
in BV [6,8,39,69], and 97%-99% in BVI [6,70]. Ideally, false positive cases in BVI reports should be less than 1%, ranging from 0.5%-10% [17,71,72].

### Conclusion

Based on the data presented, it may be concluded that (1) thyroid nodules in MNG may harbor malignancy similar to those of STN, (2) the most significant independent predictor of malignancy is the presence of micro-calculcations (by US) in MNG in addition to suspicious cervical LNs by US, and FNA (Bethesda VI) in both MNG and STN, and (3) other predictors of malignancy include solid composition of the nodule, incomplete halo and ill-defined margins in MNG, as well complex composition and peri-nodular vascularity in STN; however, these are only significant on univariate analysis.

### Conflict of Interest

Authors have no conflict of interest to disclose.

### References

1. Gharib H, Papini E, Paschke R, Duh DS, Valcavi R, et al. (2010) American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J Endocrinol Invest 33: 51-56.
2. Hegedus L (2004) The thyroid nodule. N Engl J Med 351: 1764-1771.
3. Maddox P, Wheeler M (2005) Approach to thyroid nodules. In: Clark OH, Duh QY, Kebebew E (eds). Textbook of Endocrine Surgery: WB Saunders 85.
4. Ezzat S, Sarti DA, Cain DR, Braunstein GD (1994) Thyroid incidentalomas: Prevalence by palpation and ultrasonography. Arch Intern Med 154: 1838-1840.
5. Tan GH, Gharib H (1997) Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 126: 226-231.
6. Cibas ES, Ali SZ (2009) The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol 132: 658-665.
7. Hamberger B, Gharib H, Melton LJ III, Goellner JR, Zinzmeister AR, et al. (1982) Fine-needle aspiration biopsy of thyroid nodules: Impact on thyroid practice and cost of care. Am J Med 73: 381-384.
8. Bongiovanni M, Spitala A, Faquin WC, Mazzucchelli L, Baloch ZW, et al. (2012) The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol 56: 333-339.
9. Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, et al. (2007) Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 111: 508-516.
10. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167-1214.
11. Marqusee E, Benson CB, Frates MC, Doubilet PM, Larsen PR, et al. (2000) Usefulness of ultrasonography in the management of nodular thyroid disease. Ann Intern Med 133: 696-700.
12. Papini E, Guglielmi R, Bianchini A, Crescenzini A, Taccogna S, et al. (2002) Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 87: 1941-1946.
13. Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, et al. (2006) Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab 91: 3411-3417.
14. Mandel SJ (2004) A 64-year-old woman with a thyroid nodule. JAMA 292: 2632-2642.
15. Luo J, McManus C, Chen H, Sippel RS (2012) Are there predictors of malignancy in patients with multinodular goiter? J Surg Res 170: 207-210.
16. Pinchera A, Aghini-Lombardi F, Antonangeli L, Vitti P (1996) Multinodular goiter. Epidemiology and prevention. Ann Ital Chir 67: 317-325.
17. Rios A, Rodriguez JM, Galindo PJ, Montoya M, Tebar FJ, et al. (2004) Utility of fine-needle aspiration for diagnosis of carcinoma associated with multinodular goitre. Clin Endocrinol 61: 732-737.

### Table VI: Multivariate analysis logistic regression of predictors of thyroid malignancy in patients with MNG

| Predictors of Malignancy | B     | SE    | P value | Odds Ratio | 95.0% CI Lower | Upper   |
|--------------------------|-------|-------|---------|------------|----------------|---------|
| Microcalcification (US)  | 1.452 | 0.453 | 0.001*  | 4.270      | 1.758          | 10.374  |
| FNA (B VI)               | 3.079 | 1.189 | 0.010*  | 21.736     | 2.114          | 223.491 |
| Suspicious cervical LN (US) | 1.538 | 0.599 | 0.010*  | 4.655      | 1.438          | 15.072  |
| Ill-defined margin (US)  | 1.056 | 0.64  | 0.099   | 2.876      | 0.82           | 10.088  |
| Solid composition (US)   | 0.794 | 0.495 | 0.202   | 2.212      | 0.839          | 5.832   |
| Intra-nodular vascularity (US) | 0.909 | 0.713 | 0.020   | 2.481      | 0.613          | 10.035  |

### Figure 1: Relation between the incidence of malignancy and FNA (Bethesda system) in patient with MNG and STN
18. Acioglu E, Yigit O, Seden N, Hug GE (2012) The predictive value of dominant nodules and the management of indeterminate group in multinodular goiter. Eur Arch Otorhinolaryngol 269: 283-287.

19. Tollin SR, Mery GM, Kelveth N, Dallas EK, Mihtal M, et al. (2000) The use of fine-needle aspiration biopsy under ultrasonogram guidance to assess the risk of malignancy in patients with a multinodular goiter. Thyroid 10: 235-241.

20. Salmaslioglu A, Erbgi Y, Dural C, Isever H, Kapran Y, et al. (2008) Predictive value of sonographic features in preoperative evaluation of malignant thyroid nodules in a multinodular goiter. World J Surg. 32: 1948-1954.

21. Sachnemchi I, Miller E, Varatharajah R, Chennya A, Carroll Z, et al. (2000) Thyroid carcinoma in single cold nodules and in cold nodules of multinodular goiters. Endocr Pract 6: 5-7.

22. Bonnema SJ, Bennedbaek FN, Ladenson PW, Hgedus L (2002) Management of the nontoxic multinodular goiter: A North American survey. J Clin Endocrinol Metab 87: 112-117.

23. Wolinski K, Szurdokarek M, Szczepanek-Paruska E, Ruchala M (2014) Usefulness of different ultrasound features of malignancy in predicting the type of thyroid lesions: a meta-analysis of prospective studies, Pol Arch Med Wewn 124: 97-104.

24. Merino S, Arrazola J, Cardenas A, Mendoza D, Me Miguel P, et al. (2011) Utility and interobserver agreement of ultrasound elastography in the detection of malignant thyroid nodules in clinical care: AJNR Am J Neuroradiol 32: 2142-2148.

25. Gietka-Czemen M, Kochman M, Bujalska K, Stachlewiesa-Nasfelet E, Zglczynski W, et al. (2010) Real-time ultrasound elastography - a new tool for diagnosing thyroid nodules. Endokrynol Pol 61: 652-657.

26. Jo VY, Stelow EB, Dustin SM, Hanley KZ (2010) Malignancy risk for fine-needle aspiration of thyroid nodules according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 134: 450-456.

27. Lee MJ, Kim EK, Kwak JY, Kim MJ (2009) Partially cystic thyroid nodules on ultrasound: probability of malignancy and sonographic differentiation. Thyroid 19: 341-346.

28. Richmond BK, O'Brien BA, Mangano W, Thompson S, Kemper S, et al. (2012) The impact of implementation of the Bethesda System for Reporting Thyroid Cytopathology on the surgical treatment of thyroid nodules. Am Surg 78: 706-710.

29. Kuru B, Gulceki NE, Gulceki MA, Dincer H (2009) Predictive index for carcinoma of thyroid nodules and its integration with fine-needle aspiration cytology. Head Neck 31: 856-866.

30. Le AR, Thompson GW, Hoyt BJ (2015) Thyroid Fine-needle aspiration biopsy: an evaluation of its utility in a community setting. J Otolaryngol Head Neck Surg 44: 12.

31. Pinchot SN, Al-Wagih H, Schaefer S, Sippel R, Chen H, et al. (2009) Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger. Arch Surg 144: 649-655.

32. McCall A, Jarosz H, Lawrence AM, Paloyan E (1986) The incidence of thyroid carcinoma in a recent series of 539 consecutive thyroidectomies for multinodular goiter. Tumori 83: 653-655.

33. Vanderhyden BC, Schofield KM, Hammers L, Udelsman R, Chhieng DC, et al. (2009) The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution. Thyroid 19: 1215-1223.

34. Miccoli P, Minuto MN, Galleri D, D'Agostino J, Basolo F, et al. (2006) Incidental thyroid carcinoma in a large series of consecutive patients operated on for benign thyroid disease. ANZ J Surg 76: 123-126.

35. Lee SH, Baek JS, Lee JY, Lim JA, Cho SY, et al. (2013) Predictive factors of malignancy in thyroid nodules with a cytodiagnostic diagnosis of follicular neoplasm. Endocr Pathol 24: 177-183.

36. Najafian A, Olson MT, Schneider EB, Zeiger MA (2015) Clinical presentation of patients with a thyroid follicular neoplasm: are there preoperative predictors of malignancy? Ann Surg Oncol 22: 3007-3013.

37. Sillery JC, Reading CC, Charbonneau JW, Henrichsen TL, Hay ID, et al. (2010) Thyroid follicular carcinoma: sonographic features of 50 cases. AJR Am J Roentgenol 194: 44-54.

38. Rago T, Fiore E, Scutari M, Santini F, Di Coscio G, et al. (2010) Male sex, single nodularity, and young age are associated with the risk of finding a papillary thyroid cancer on fine-needle aspiration cytology in a large series of patients with nodular thyroid disease. Eur J Endocrinol 162: 763-770.

39. Macias CA, Arumugam D, Arlow RL, Eng OS, Lu S, et al. (2015) A risk model to determine surgical treatment in patients with thyroid nodules with indeterminate cytology. Ann Surg Oncol 22: 1527-1532.

40. Baloch ZW, Fleisher S, LioVolsi VA, Gupta PK (2002) Diagnosis of “folicular neoplasm” - a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol 26: 41-44.

41. Davis NL, Gordon M, Germann E, Roberts RE, McGregor GI, et al. (1991) Clinical parameters predictive of malignancy of thyroid follicular neoplasms. Am J Surg 161: 567-569.

42. Akslen LA (1993) Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer 72: 2680-2685.

43. Cady B, Rossi R (1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104: 947-953.

44. Hay ID, Bergstralh EJ, Goelnter JR, Ebersold JR, Grant CS, et al. (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114: 1050-1057.

45. Hoang JK, Lee WK, Lee M, Johnson D, Farrell S, et al. (2007) US Features of thyroid malignancy: pearls and pitfalls. Radiographics 27: 847-860.

46. Schlinkert RT, van Heerden JA, Goelnter JR, Garbhi H, Smith SL, et al. (1997) Factors that predict malignant thyroid lesions when fine-needle aspiration is "suspicious for follicular neoplasm". Mayo Clin Proc 72: 913-916.

47. Corrias A, Einaudi S, Chioboli E, Weber G, Crino A, et al. (2001) Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches. J Clin Endocrinol Metab 86: 4644-4646.

48. Frates MC, Benson CB, Charbonneau JW, Cibas ES, Clark OH, et al. (2005) Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 237: 794-800.

49. Khoo ML, Asa SL, Witterick I, Freeman JL (2002) Thyroid calcification and its association with thyroid carcinoma. Head Neck 24: 651-655.

50. Chan BK, Desser TS, McDougall IR, Weigel RJ, Jeffrey RB, et al. (2003) Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med 22: 83-90.

51. Cappelli C, Castellano M, Piora I, Cumetti D, Agostì B, et al. (2007) The predictive value of ultrasound findings in the management of thyroid nodules. QJM 100: 29-35.

52. Kim EK, Park CS, Chung WY, Oh KK, Kim DI, et al. (2002) New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol 178: 687-691.

53. Mandel SJ (2004) Diagnostic use of ultrasonography in patients with nodular thyroid disease. Endocr Pract 10: 246-252.

54. Moon WJ, Jung SL, Lee JH, Na DG, Baek JH, et al. (2008) Benign and malignant thyroid nodules: US differentiation–multicenter retrospective study. Radiology 247: 762-770.

55. Iannuccilli JD, Cronan JJ, Monchik JM (2004) Risk for malignancy of thyroid nodules as assessed by sonographic criteria: the need for biopsy. J Ultrasound Med 23: 1455-1464.

56. Cappelli C, Castellano M, Piora I, Gandonio E, De Martino E, et al. (2006) An ultrasound reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 94: 1748-1751.
64. Bombil I, Bentley A, Kruger D, Luvhengo TE (2014) Incidental cancer in multinodular goitre post thyroidectomy. S Afr J Surg 52: 5-9.

65. Ylagan LR, Farkas T, Dehner LP (2004) Fine needle aspiration of the thyroid: a cytohistologic correlation and study of discrepant cases. Thyroid 14: 35-41.

66. McCoy KL, Jabbour N, Ogilvie JB, Ohori NP, Carty SE, et al. (2007) The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. Surgery 142: 837-844.

67. Yang J, Schnadig V, Logrono R, Wasserman PG (2007) Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer 111: 306-315.

68. Deveci MS, Deveci G, LiVolsi VA, Baloch ZW (2006) Fine-needle aspiration of follicular lesions of the thyroid. Diagnosis and follow-Up. CytoJournal 3: 9.

69. Wu HH, Rose C, Elsheikh TM (2012) The Bethesda system for reporting thyroid cytopathology: An experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy. Diagn Cytopathol 40: 398-403.

70. Poller DN, Ibrahim AK, Cummings MH, Mikel JJ, Boote D, et al. (2000) Fine-needle aspiration of the thyroid. Cancer 90: 239-244.

71. Tuttle RM, Lemar H, Burch HB (1998) Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasm by fine-needle aspiration. Thyroid 8: 377-383.

72. Davoudi MM, Yeh KA, Wei JP (1997) Utility of fine-needle aspiration cytology and frozen-section examination in the operative management of thyroid nodules. Am Surg 63: 1084-1089.